Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144430 · ClinicalTrials.gov registry record · Phase 2
Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
A Phase 2 study, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00144430 is a Phase 2 study that has completed, run by Ann & Robert H Lurie Children's Hospital of Chicago. The registered enrollment target is 60 participants.
The verdict
NCT00144430, a Phase 2 study, has completed, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a multicenter trial through the Pediatric Blood and Marrow Transplant Consortium. The Primary hypothesis of this study is that because of its effect as a potent immunosuppressive agent targeting lymphocytes, pentostatin will show a sustained response in pediatric subjects with severe chronic GVHD. Secondary hypotheses include that the infection and toxicity rate of pentostatin in this setting will be acceptable given its lack of severe myelosuppression, and subjects with refractory chronic GVHD will have significant QOL impairment and symptomatology. These may change as subjects are being treated for their chronic GVHD with pentostatin.
Interventions
- DRUG Pentostatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144430
The ClinicalTrials.gov registry entry for NCT00144430 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pentostatin is the first listed.
NCT00144430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00144430 about?
NCT00144430 is a clinical study titled "Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children". This is a multicenter trial through the Pediatric Blood and Marrow Transplant Consortium. The Primary hypothesis of this study is that because of its effect as a potent immunosuppressive agent targeting lymphocytes, pentostatin will show a sustained response in pediatric subjects with severe chroni...
What is the current status of trial NCT00144430?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2004-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00144430?
The interventions under investigation include: Pentostatin (DRUG).
Who is sponsoring clinical trial NCT00144430?
This trial is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago, which has 159 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.